Bank of New York Mellon Corp Has $676,000 Stake in Pulse Biosciences, Inc. (NASDAQ:PLSE)

Bank of New York Mellon Corp lessened its holdings in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) by 3.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 38,811 shares of the company’s stock after selling 1,529 shares during the period. Bank of New York Mellon Corp owned about 0.06% of Pulse Biosciences worth $676,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its position in Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock worth $2,598,000 after buying an additional 97,565 shares in the last quarter. State Street Corp lifted its position in shares of Pulse Biosciences by 17.8% during the 3rd quarter. State Street Corp now owns 461,333 shares of the company’s stock valued at $8,092,000 after acquiring an additional 69,696 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Pulse Biosciences during the 3rd quarter worth $588,000. Geode Capital Management LLC grew its holdings in shares of Pulse Biosciences by 7.8% during the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock worth $8,020,000 after purchasing an additional 33,200 shares in the last quarter. Finally, Barclays PLC increased its position in shares of Pulse Biosciences by 361.4% in the third quarter. Barclays PLC now owns 30,306 shares of the company’s stock worth $530,000 after purchasing an additional 23,738 shares during the period. 76.95% of the stock is owned by institutional investors.

Pulse Biosciences Stock Down 0.3 %

Shares of Pulse Biosciences stock opened at $15.80 on Thursday. The company has a 50 day moving average of $18.87 and a 200-day moving average of $18.18. Pulse Biosciences, Inc. has a 1-year low of $6.60 and a 1-year high of $25.00.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a research report on Thursday, January 2nd.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.